series-a
Stage
1
Investors
About
ProLynx develops a hydrogel-based microsphere drug delivery platform with tunable linker chemistry to enable ultra-long-acting, extended-release therapeutics for obesity, diabetes, and related metabolic diseases, supporting dosing intervals of up to 90 days.
Explore ProLynx's full profile on Brouky
Funding rounds, investor list, and risk signals — unlock with a subscription.